The BVA-100 (Blood Volume Analyzer) is a revolutionary instrument, developed by DAXOR Corporation and approved by the FDA, to precisely measure blood volume in the human body.

Read More

Key Features

  • Superior  blood volume measurement
  • Results in under 1 hour
  • Clinically proven — significant survival benefits

Latest News

Sunset over manhattan

Daxor Corporation Appoints Michael Feldschuh as Executive Vice President

Feldschuh to head business development and strategic initiatives Daxor Corp (AMEX: DXR) announced today that it has appointed Michael Feldschuh as Executive Vice President, to head business development and strategic initiatives for Daxor Corporation as part of the firm’s effort to build its medical device business. “We have exciting strategic goals for our medical device […]

Read More

Three Doctors Standing Outside A Hospital

Daxor Corporation Announces A Major Study with the Mayo Clinic

Daxor Corporation, (NYSE MKT: DXR) announced its funding of a major study today for treating heart failure. The principal investigator for the study is Wayne Miller, M.D., PhD. Dr. Miller and his associates previously conducted a study on heart failure patients which was recently published in the Journal of the American College of Cardiology-Heart Failure. […]

Read More


“BVA allows physicians to determine an accurate status on heart failure patients.”

Shamsuddin Khwaja
Cardiothoracic Surgeon
Fresno Heart and Surgical Hospital

“We are excited to have acquired the blood volume analyzer. We see this as a valuable tool for guiding therapy for our heart failure patients.”

Dr. Gamal Sidarous, Nuclear Medicine Physician at Banner Good Samaritan Medical Center 

“I view this as an opportunity to improve patient outcomes for those associated with poor prognosis.  I believe that this advanced testing method will become an essential service in treating heart failure and other life threatening conditions.”

Max Akin, president of North Alabama RadioPharmacy